论文部分内容阅读
供者淋巴细胞输注(DLI)治疗18例(男10例,女8例,年龄23～51岁)异基因骨髓移植(allo-BMT)后细胞遗传学(6例)或血液学(共12例,慢性期5例、加速期6例、原始细胞转化1例)检测证实复发的慢性髓细胞白血病(CML)患者。患者分为两组,A组8例,输入1～2×10~(?)个/kg完全单采的白细胞,B组10例,输入的供者细胞数逐渐增加,设计的方案为第1、22天输入2
Sixteen patients (10 males and 8 females, aged 23-51 years) who underwent allogeneic bone marrow transplantation (allo-BMT) after donor lymphocyte infusion (DLI) were treated with cytogenetics (6) or hematology 5 cases of chronic phase, 6 cases of accelerated phase and 1 case of primary cell transformation) were detected in patients with chronic myeloid leukemia (CML) who had proven relapse. The patients were divided into two groups. A group of 8 patients received 1 ~ 2 × 10 ~ (?) Cells / kg of totally apheresis leukocytes, and 10 patients in group B received more donor cells. The designed protocol was 1 Enter 2 for 22 days